Quantifying Intra-Arterial Verapamil Response as a Diagnostic Tool for Reversible Cerebral Vasoconstriction Syndrome

• Published in: American journal of neuroradiology : AJNR Vol. 41; no. 10; pp. 1869 - 1875
• Main Authors: Sequeiros, J M, Roa, J A, Sabotin, R P, Dandapat, S, Ortega-Gutierrez, S, Leira, E C, Derdeyn, C P, Bathla, G, Hasan, D M, Samaniego, E A
• Format: Journal Article
• Language: English
• Published: United States American Society of Neuroradiology 01-10-2020
• Subjects: Adult; Angiography, Digital Subtraction; Female; Humans; Infusions, Intra-Arterial; Interventional; Male; Middle Aged; Vasoconstriction - drug effects; Vasodilator Agents - pharmacology; Vasospasm, Intracranial - diagnosis; Verapamil - pharmacology
• DOI: 10.3174/ajnr.A6772
• EISSN: 1936-959X
• ISSN: 0195-6108

There is mounting evidence supporting the benefit of intra-arterial administration of vasodilators in diagnosing reversible cerebral vasoconstriction syndrome. We prospectively quantified the degree of luminal diameter dilation after intra-arterial administration of verapamil and its accuracy in diagnosing reversible cerebral vasoconstriction syndrome.
Patients suspected of having intracranial arteriopathy on noninvasive imaging and referred for digital subtraction angiography were enrolled in a prospective registry. Intra-arterial verapamil was administered in vascular territories with segmental irregularities. The caliber difference (Caliber
- Caliber
) and the proportion of caliber change ([(Caliber
- Caliber
)/Caliber
] × 100%) were used to determine the response to verapamil. The diagnosis of reversible cerebral vasoconstriction syndrome was made on the basis of clinical and imaging features at a follow-up appointment, independent of the reversibility of verapamil. Receiver operating characteristic curve analysis was performed to determine the best threshold.
Twenty-six patients were included, and 9 (34.6%) were diagnosed with reversible cerebral vasoconstriction syndrome. A total of 213 vascular segments were assessed on diagnostic angiography. Every patient with a final diagnosis of reversible cerebral vasoconstriction syndrome responded to intra-arterial verapamil. The maximal proportion of change (
< .001), mean proportion of change (
= .002), maximal caliber difference (
= .004), and mean caliber difference (
= .001) were statistically different between patients with reversible cerebral vasoconstriction syndrome and other vasculopathies. A maximal proportion of change  ≥32% showed a sensitivity of 100% and a specificity of 88.2% to detect reversible cerebral vasoconstriction syndrome (area under the curve = 0.951). The Reversible Cerebral Vasoconstriction Syndrome-2 score of  ≥5 points achieved a lower area under the curve (0.908), with a sensitivity of 77.8% and a specificity of 94.1%.
Objective measurement of the change in the arterial calibers after intra-arterial verapamil is accurate in distinguishing reversible cerebral vasoconstriction syndrome from other vasculopathies. A proportion of change  ≥32% has the best diagnostic performance.